Education
About Us
Working with TipRanks
Follow Us
Benitec Biopharma Ltd (BNTC)
NASDAQ:BNTC
BNTC Stock Chart & Stats
$10.79
<$0.01(0.09%)
At close: 4:00 PM EST
$10.79
<$0.01(0.09%)
Day’s Range― - ―
52-Week Range$9.70 - $17.15
Previous CloseN/A
Volume10.71K
Average Volume (3M)313.52K
Market Cap
$420.23M
Enterprise Value$488.77M
Total Cash (Recent Filing)$94.48M
Total Debt (Recent Filing)$817.00K
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Feb 16, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding33,862,225
10 Day Avg. Volume301,154
30 Day Avg. Volume313,522
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)4.35
Price to Sales (P/S)0.00
P/FCF Ratio-17.95
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue879.08
Enterprise Value/Gross Profit5.37K
Enterprise Value/Ebitda-9.99
Forecast
1Y Price Target
$26.00Price Target Upside140.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.27
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsThe oculopharyngeal muscular dystrophy (OPMD) responder analysis designed by Benitec shows a 100% responder rate, supported by the robust mechanism of action and the clinical meaningfulness of selected efficacy outcome measures.
Financial StabilityBenitec Biopharma recently completed an equity financing transaction involving the sale of ~7.4M shares of common stock at a price of $13.50 per share, which meaningfully strengthens the company's balance sheet and should facilitate funding of the clinical development of BB-301 through pivotal assessment.
Regulatory ProgressBB-301 development pathway appears relatively straightforward due to close communication with FDA regulators, with the company receiving Fast Track designation and Orphan Drug designation from both the FDA and the European Medicines Agency.
Bears Say
Financial ChallengesBNTC reported a net loss of approximately $16.1M, highlighting financial challenges despite the cash runway.
Increased ExpensesThere was a significant increase in SG&A expenses due to higher employment-related costs and share-based compensation.
Price Target AdjustmentThe 12-month price target is decreased to $32 from the prior $35 per share to account for the equity dilution impact from the most recent transaction.
Benitec Biopharma News
BNTC FAQ
What was Benitec Biopharma Ltd’s price range in the past 12 months?
Benitec Biopharma Ltd lowest stock price was $9.70 and its highest was $17.15 in the past 12 months.
What is Benitec Biopharma Ltd’s market cap?
Benitec Biopharma Ltd’s market cap is $420.23M.
When is Benitec Biopharma Ltd’s upcoming earnings report date?
Benitec Biopharma Ltd’s upcoming earnings report date is Feb 16, 2026 which is in 59 days.
How were Benitec Biopharma Ltd’s earnings last quarter?
Benitec Biopharma Ltd released its earnings results on Nov 14, 2025. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.45 by $0.23.
Is Benitec Biopharma Ltd overvalued?
According to Wall Street analysts Benitec Biopharma Ltd’s price is currently Undervalued.
Does Benitec Biopharma Ltd pay dividends?
Benitec Biopharma Ltd pays a Notavailable dividend of $0.765 which represents an annual dividend yield of N/A. See more information on Benitec Biopharma Ltd dividends here
What is Benitec Biopharma Ltd’s EPS estimate?
Benitec Biopharma Ltd’s EPS estimate is -0.22.
How many shares outstanding does Benitec Biopharma Ltd have?
Benitec Biopharma Ltd has 33,862,225 shares outstanding.
What happened to Benitec Biopharma Ltd’s price movement after its last earnings report?
Benitec Biopharma Ltd reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.45. Following the earnings report the stock price went up 2.812%.
Which hedge fund is a major shareholder of Benitec Biopharma Ltd?
Currently, no hedge funds are holding shares in BNTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Benitec Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.00 (140.96% Upside)
$26.00 (140.96% Upside)
Blogger Sentiment
Bullish
BNTC Sentiment 100%
Sector Average 68%
Sector Average 68%
Insider Transactions
Bought Shares
Worth $20.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.50%
12-Months-Change
Fundamentals
Return on Equity
-43.71%
Trailing 12-Months
Asset Growth
39.63%
Trailing 12-Months
Company Description
Benitec Biopharma Ltd
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
BNTC Stock 12 Month Forecast
Average Price Target
$26.00
▲(140.96% Upside)
Technical Analysis
Tvardi Therapeutics
―
Assembly Biosciences
―
Rocket Pharmaceuticals
―
4D Molecular Therapeutics
―
Aura Biosciences Inc
―
Ownership Overview
5.76% Insiders
7.48% Mutual Funds
41.27% Other Institutional Investors
40.98% Public Companies and
Individual Investors